Document Detail

Mineralcorticoid Antagonists in Heart Failure.
MedLine Citation:
PMID:  25217431     Owner:  NLM     Status:  Publisher    
Mineralocorticoid receptor antagonists (MRAs) have become mandated therapy in patients with reduced ejection fraction (systolic) heart failure (HF) across all symptom classes. These agents should also be prescribed in the early post-myocardial infarction setting in those with reduced ejection fraction and either HF symptoms or diabetes. This article explores the pathophysiological role of aldosterone, an endogenous ligand for the mineralcorticoid receptor (MR), and summarizes the clinical data supporting guideline recommendations for these agents in systolic HF. The use of MRAs in novel areas beyond systolic HF ejection is also explored. Finally, the current status of newer agents will be examined.
Emilia D'Elia; Henry Krum
Publication Detail:
Type:  REVIEW     Date:  2014-8-19
Journal Detail:
Title:  Heart failure clinics     Volume:  10     ISSN:  1551-7136     ISO Abbreviation:  Heart Fail Clin     Publication Date:  2014 Oct 
Date Detail:
Created Date:  2014-9-13     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101231934     Medline TA:  Heart Fail Clin     Country:  -    
Other Details:
Languages:  ENG     Pagination:  559-564     Citation Subset:  -    
Copyright Information:
Copyright © 2014 Elsevier Inc. All rights reserved.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Time and Technology Will Tell: The Pathophysiologic Basis of Neurohormonal Modulation in Heart Failu...
Next Document:  Current Perspectives on Hydralazine and Nitrate Therapies in Heart Failure.